

ACR damage index (SDI) and HR-QoL by EQ-5D were measured. Bivariate analysis through chi squared and U Mann Whitney Multivariate analysis was performed by logistic regression to adjust for significant associations. Statistical analysis for related samples was evaluated with Mc. Nemar test.

Results We analyzed 400 Colombian patients. Baseline median age was 49 years (15 IQR) with median age at diagnosis and disease duration of 37 years (17 IQR) and 9 years (13 IQR) respectively. There were 94% female patients and 17.3% late onset SLE. Most frequent clinical manifestations were hematological (82.8%), mucocutaneous (75.3%) and nephritis (33.8%). Only 4.5% had neurological involvement. The mean SLEDAI were 1.18 and 0.65 at first and second measurement respectively, in the first measurement 97.1% of the patients had a SLEDAI \leq 4. The mean SDI was 0.7275 at first measurement and 0.985 at the second measurement. Although SDI was associated to various dimensions of HR-QoL measured by ED-5D, disease activity was not related (See table 1).

Conclusions In SLE Colombian patients with a established disease and an altered HR-QoL, low disease activity is not related with HR-QoL when measured by EQ-5d. In the present study, it is highlighted that while disease activity decreases, damage increases. Damage accrual has a relation with HR-QoL in the short term. The impact and correlation must be better defined in a long-term follow-up. The associated effect on HRQOL emphasizes the need for strategies to reduce the risk of cumulative organ damage.

CS-36 RECOMMENDATIONS FOR THE ASSESSMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN CANADA

¹Stephanie Keeling*, ²Zainab Alabdurubalnabi, ²Antonio Avina-Zubieta, ³Susan Barr, ⁴Louise Bergeron, ⁵Sasha Bematsky, ⁶Josiane Bourre-Tessier, ³Ann Clarke, ⁶Alexandra Baril-Dionne, ²Jan Dutz, ²Stephanie Ensworth, ³Aurore Fifi-Mah, ⁷Paul R Fortin, ⁸Dafna Gladman, ⁹Derek Haaland, ¹⁰John G Hanly, ¹¹Linda T Hiraki, ⁶Sara Hussein, ⁹Kimberly Legault, ¹¹Deborah Levy, ¹²Lily Lim, ⁹Mark Matsos, ¹³Emily G McDonald, ⁸Jorge Medina-Rosas, ¹⁴Jordi Pardo Pardi, ¹²Christine Peschken, ⁵Christian Pineau, ¹⁵Janet Pope, ¹⁶Tamara Rader, ²Jen Reynolds, ¹¹Earl Silverman, ⁸Konstantinos Tselios, ⁶Manon Suitner, ⁸Murray Urowitz, ⁸Zahi Touma, ⁵Evelyn Vinet, ¹⁷Nancy Santesso. ¹Division of Rheumatology, Department of Medicine, University of Alberta; ²Division of Rheumatology, Department of Medicine, University of British Columbia; ³Division of Rheumatology, Department of Medicine, Cumming School of Medicine, University of Calgary; ⁴Louise Bergeron, Canadian Arthritis Patient Alliance; ⁵Division of Rheumatology, Department of Medicine, McGill University; ⁶Division of Rheumatology, Department of Medicine, Université de Montreal; ⁷Division of Rheumatology, Department of Medicine, Université Laval; ⁸Institute of Health Policy, Management and Evaluation, University of Toronto; ⁹Division of Rheumatology, Department of Medicine, McMaster University; ¹⁰Division of Rheumatology, Department of Medicine, Dalhousie University; ¹¹Division of Rheumatology, Hospital for Sick Children, Department of Pediatrics University of Toronto; ¹²Division of Rheumatology, Department of Medicine, University of Manitoba; ¹³General Internal Medicine, McGill University Health Centre, McGill University; ¹⁴Cochrane Musculoskeletal Group, University of Ottawa; ¹⁵Division of Rheumatology, Department of Medicine, Western University; ¹⁶Canadian Agency for Drugs and Technologies in Health; ¹⁷Department of Health Research Methods, Evidence and Impact, McMaster University

10.1136/lupus-2018-lsm.71

Background To develop GRADE-based recommendations for the diagnosis and monitoring of systemic lupus erythematosus patients in Canada.

Methods Recommendations were developed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach. The Canadian SLE Working Group (panel of Canadian rheumatologists and patient representative

Abstract CS-36 Table 1 Summary of recommendations with strength of evidence for the diagnosis and monitoring of SLE in Canada

Recommendation	Strength of Recommendation; Quality of Evidence
We recommend that all adult and pediatric patients suspected of SLE be referred to a lupus specialist, most often a rheumatologist, to confirm diagnosis and be involved in ongoing care	strong recommendation; moderate quality evidence
For adult and pediatric patients with SLE, we suggest assessing disease activity with a validated instrument of disease activity during baseline and follow up visits.	conditional recommendation, low quality evidence
For adult and pediatric patients with SLE, we suggest assessing disease activity with a validated instrument of disease activity during baseline and follow up visits	conditional recommendation, low quality evidence
For adult lupus patients, we recommend that indicators of obesity, smoking status, diabetes, blood pressure and a basic lipid profile be measured upon diagnosis of SLE and be reassessed periodically according to current recommendations in the general population and be used to inform the cardiovascular risk assessment.	strong recommendation, moderate quality evidence
For adult patients with SLE, we suggest assessing the risk of osteoporosis and fractures every 1 to 3 years using a detailed history and focused physical examination, and measuring bone mineral density in patients with other risk factors according to recommendations in the general population.	conditional recommendation, low quality evidence
For all adults with SLE, we suggest screening 25-hydroxyvitamin D as part of the assessment for risk of osteoporosis and fractures	strong recommendation, moderate quality evidence
For adults and paediatric patients with a diagnosis of SLE and high risk behaviours for HCV acquisition, we recommend screening for Hepatitis C and repeating according to recommendations in the general population. For all other adult and paediatric patients with a diagnosis of SLE we suggest screening for Hepatitis C and repeating according to recommendations in the general population	conditional recommendation, low quality evidence
For adult patients with SLE who do not have clinical symptoms suggestive of osteonecrosis, we suggest not screening for or performing investigations for osteonecrosis. For patients who have suspected clinical symptoms of osteonecrosis, we suggest radiographs as the initial imaging modality rather than MRI or bone scan with SPECT according to recommendations in the general population.	conditional recommendation, low quality evidence
For women with SLE, we suggest that anti-Ro and anti-La antibodies be measured immediately prior to pregnancy or during the first trimester.	conditional recommendation, low quality evidence
For pregnant women with SLE, we suggest that uterine and umbilical Doppler studies be performed in the second or third trimester, or at the time of a suspected flare.	conditional recommendation, low quality evidence
For women with prior or active lupus nephritis who are pregnant, we suggest measuring serum creatinine and urine protein to creatinine ratio every 4–6 weeks, or more frequently if clinically indicated. We suggest blood pressure and urinalysis be measured prior to pregnancy and every 4–6 weeks until 28 weeks, every 1–2 weeks until 36 weeks and then weekly until delivery.	conditional recommendation; low quality evidence

All female adult patients with SLE who are or have been sexually active, regardless of sexual orientation, we suggest annual cervical cancer screening rather than screening every 3 years at least up to the age of 69.	conditional recommendation; low quality evidence
We recommend that adults and children with SLE receive an annual inactivated influenza vaccination in a single dose.	strong recommendation, moderate quality evidence
For adults and paediatric patients with a diagnosis of SLE and high risk behaviours for HBV and/or HCV acquisition, we recommend screening for Hepatitis B surface antigen and/or Hepatitis C and repeating according to recommendations for the general population. For patients being considered for immunomodulatory therapy, we suggest screening for HBV before starting treatment	conditional recommendation, low quality evidence

from CAPA (Canadian Arthritis Patient Alliance)) was created. A series of questions for recommendation development were identified based on the results of a survey of SLE practice patterns of members of the Canadian Rheumatology Association (CRA). Systematic literature reviews of randomized controlled trials and observational studies were conducted. Evidence to Recommendation Tables were prepared and presented to the panel at two face-to-face meetings for discussion and voting during and post-meeting online.

Results There were a total of fourteen recommendations for assessing and monitoring lupus patients (table 1). Three recommendations focused on disease activity and damage assessment suggesting that a validated disease activity score per visit and annual damage score were important in evaluating the patient. One strong recommendation was made for cardiovascular risk assessment with conditional recommendations for osteoporosis (2) and osteonecrosis (1). Three conditional recommendations were made regarding peripartum assessments, one on cervical cancer screening and two on hepatitis B and C screening. A strong recommendation was made for annual influenza vaccination.

Conclusions These are the first GRADE-based recommendations for the diagnosis and monitoring of SLE internationally. Evidence is largely of moderate to low quality resulting in more conditional versus strong recommendations. Further studies of higher quality and special attention to pediatric lupus populations are needed.

Acknowledgements The authors are members of the Canadian SLE Working Group which was created to develop these recommendations.

CS-37 PREVALENCE OF COGNITIVE IMPAIRMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS ASSESSED BY A COMPREHENSIVE NEUROPSYCHOLOGICAL BATTERY

¹Zahi Touma*, ²Robin Green, ³Lisa Engel, ⁴Carmela Tartaglia, ²Lesley Ruttan, ²Sabrina Lombardi, ³Nicole Anderson, ³Jiandong Su, ³Kenneth Colosimo, ³Michelle Vitti, ³Dennise Bonilla, ³Joan Wither, ⁵Marvin Fritzer, ⁶Dorcas Beaton. ¹University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto Western Hospital; ²Toronto Rehabilitation Institute; ³University of Toronto, Toronto Western Hospital; ⁴University of Toronto, Krembil Neurosciences Centre; ⁵University of Calgary; ⁶St Michael's Hospital

10.1136/lupus-2018-lsm.72


Background Cognitive impairment (CI) is a common neurobehavioural manifestation of systemic lupus erythematosus (SLE). In our recent systematic review, the prevalence of CI was 38% (95% CI 33% to 43%) with a wide variation (15%–79%), which may be due to differences in CI definitions and selection of neuropsychological tests across studies. We aim to report the prevalence of CI in a large cohort using a comprehensive battery (CB) of tests in which we operationalized the classification of CI.

Methods Consecutive consenting SLE patients, aged 18–65 years, who attended a single center (Jul 2016-Feb 2018) were recruited. Patients were administered a CB that evaluates the major cognitive domains: Manual motor speed and dexterity, simple attention and processing speed, visual-spatial construction, verbal fluency, learning and memory (visuospatial and memory), executive functioning (untimed and timed).

Patient scores were compared to a normative sample of age- and gender-matched healthy controls to obtain z-scores. CI was operationalized on the CB as a z-score of ≤ -1.5 (as compared to controls) on ≥ 2 domains or $z \leq -2.0$ on ≥ 1 domain. Descriptive statistics were used.

Results Of the 199 patients (89% female), the mean age at SLE diagnosis was 28.3 ± 10.4 and disease duration at enrolment was 14.3 ± 10.2 years. The prevalence of CI was 37.7% ($z \leq -1.5$ in ≥ 2 domains) and 49.8% ($z \leq -2.0$ in ≥ 1 domains).

Prevalence of patients with domain z-scores of ≤ -1.5 and ≤ -2.0 varied from 3.0%–46.2% and 0.5%–25.1% respectively (figure 1). The most affected domain was learning and memory (visuospatial and memory) in 92 (46.2%) patients based on $z \leq -1.5$ on ≥ 2 subtests and 50 (25.1%) patients based on $z \leq -2.0$ in ≥ 1 subtest.



Abstract CS-37 Figure 1 Prevalence of patients with domain Z-scores of ≤ -1.5 and ≤ -2.0

Conclusion Prevalence of CI using our CB ranged between 37.7%–49.8% ($z \leq -1.5$ in ≥ 2 domains and $z \leq -2.0$ in ≥ 1 domains respectively), which was higher than the pooled prevalence from previous reports of 38%. These differences in CI prevalence across studies could be attributed to different factors including the heterogeneity in patients' demographics/comorbidities, sample size, the use of different metrics to determine CI, and the lack of a standardized definition of CI. Further studies are required to identify the best definition for CI and its metrics.

Acknowledgment This project is funded by the Arthritis Society and the Physicians' Services Incorporated Foundation.